Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 380

Sort by

Sort Order Select

Journal Articles

Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection

Alissa Visram, Dirk Larson, Aaron Norman, Angela Dispenzieri, David Murray, Robert Kyle, S. Vincent Rajkumar, Susan Slager, Shaji Kumar, Celine Vachon

Blood (2025) 145 (3): 325–333.

https://doi.org/10.1182/blood.2024025415

Published: 2025

Includes: Supplemental data

Journal Articles

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji Kumar, Angela Dispenzieri, Sagar Lonial, Brian G. M. Durie, Paul G. Richardson, Saad Z. Usmani, Antje Hoering, Robert Z. Orlowski

Blood (2025) 145 (1): 75–84.

https://doi.org/10.1182/blood.2024025939

Published: 2025

Includes: Supplemental data

Journal Articles

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Rajshekhar Chakraborty, Saurabh Zanwar, Ute Hegenbart, Divaya Bhutani, Morie A. Gertz, Angela Dispenzieri, Shaji Kumar, Anita D’Souza, Anannya Patwari, Andrew Cowan, GuiZhen Chen, Paolo Milani, Giovanni Palladini, Vaishali Sanchorawala, Geethika Bodanapu, Stefan O. Schönland, Suzanne Lentzsch, Eli Muchtar

Blood (2024) 144 (25): 2613–2624.

https://doi.org/10.1182/blood.2024025899

Published: 2024

Includes: Supplemental data

Journal Articles

Bringing Hematological Malignancy Clinical Trials to Patients: Mayo Clinic LLS Impact Experience

Jamie Johnston, Katie J. Doane, Wesley Waszak, Carolyn Flock, Arushi Khurana, Nina Logan, Nanci Hawley, Eyad Al-Hattab, Akeem R. Lewis, Jonathan Ticku, Amir Yosef, Stephen M. Ansell, Shaji Kumar, Sameer A. Parikh, Mithun V Shah, Thomas E. Witzig, Grzegorz S. Nowakowski

Blood (2024) 144 (Supplement 1): 784.

https://doi.org/10.1182/blood-2024-205791

Published: 2024

Journal Articles

Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy

Blood (2024) 144 (Supplement 1): 287.

https://doi.org/10.1182/blood-2024-202589

Published: 2024

Journal Articles

Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 592.

https://doi.org/10.1182/blood-2024-201056

Published: 2024

Journal Articles

The Mutational Landscape of Extramedullary Multiple Myeloma Reveals Novel Biologic Insights and Potential Therapeutic Targets for Exploration

Saurabh Zanwar, Joseph Novak, Michael D Howe, Moritz Binder, Wilson I. Gonsalves, Esteban Braggio, Vincent Rajkumar, Dragan Jevremovic, Surendra Dasari, Shaji Kumar

Blood (2024) 144 (Supplement 1): 2744.

https://doi.org/10.1182/blood-2024-203350

Published: 2024

Journal Articles

Single-Cell Spatial Proteomic Characterization of Clonal Plasma Cell and Immune Cell Metabolism within the Bone Marrow Microenvironment in High-Risk Smoldering Multiple Myeloma and Its Association with Progression to Multiple Myeloma

Cinnie Soekojo, Susan M. Geyer, Emmanuel Contreras Guzman, Kaitlyn Whitaker, Shaji Kumar, Vincent Rajkumar, Joselle Cook, Yogesh Chawla, Francis Buadi, Angela Dispenzieri, Moritz Binder, Rafael Fonseca, Taro Hitosugi, Dragan Jevremovic, Wilson I. Gonsalves, Jose C. Villasboas Bisneto

Blood (2024) 144 (Supplement 1): 1880.

https://doi.org/10.1182/blood-2024-207440

Published: 2024

Journal Articles

Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis

Blood (2024) 144 (Supplement 1): 2400.

https://doi.org/10.1182/blood-2024-209102

Published: 2024

Journal Articles

Feasibility and Implementation of the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Blood (2024) 144 (Supplement 1): 2393.

https://doi.org/10.1182/blood-2024-203892

Published: 2024

Journal Articles

Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax

Marcella Kaddoura, J Erin Wiedmeier-Nutor, Vikas A. Gupta, Bachisio Ziccheddu, Suganti Shivaram, Hongwei Tang, Rodrigo Fonseca, Michael Durante, Shannon M Matulis, Tomas Jelinek, Ola Landgren, Constantine S Mitsiades, P. Leif Bergsagel, Esteban Braggio, Lawrence H. Boise, Rafael Fonseca, Shaji Kumar, Francesco Maura, Linda B. Baughn

Blood (2024) 144 (Supplement 1): 249.

https://doi.org/10.1182/blood-2024-204071

Published: 2024

Journal Articles

Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 83.

https://doi.org/10.1182/blood-2024-202098

Published: 2024

Journal Articles

Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4704.

https://doi.org/10.1182/blood-2024-201052

Published: 2024

Journal Articles

Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma

Nadine Abdallah, Matthew Rees, Supriya Gupta, Mohammed Elhaj, Radhika Bansal, Terri Menser, Gavin Schaeferle, Joselle Cook, Taxiarchis Kourelis, Rahma M Warsame, Wilson I. Gonsalves, Prashant Kapoor, Francis Buadi, Suzanne R Hayman, David Dingli, Morie A. Gertz, Yi Lin, Shaji Kumar

Blood (2024) 144 (Supplement 1): 4695.

https://doi.org/10.1182/blood-2024-211768

Published: 2024

Journal Articles

Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4716.

https://doi.org/10.1182/blood-2024-211755

Published: 2024

Journal Articles

Radiomics-Based Biomarkers for Risk Stratification in Newly Diagnosed Multiple Myeloma

Jacob T Shreve, Michael D Howe, Emmanuel Contreras Guzman, Charalampos Charalampous, Wilson I. Gonsalves, Francis Buadi, Taxiarchis Kourelis, Suzanne R Hayman, Morie A. Gertz, Rafael Fonseca, S. Vincent Rajkumar, Surendra Dasari, Matthew P. Thorpe, Stephen Broski, Shaji Kumar, Moritz Binder

Blood (2024) 144 (Supplement 1): 4711.

https://doi.org/10.1182/blood-2024-202022

Published: 2024

Journal Articles

Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy

Blood (2024) 144 (Supplement 1): 2372.

https://doi.org/10.1182/blood-2024-210474

Published: 2024

Journal Articles

Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry

Kenneth J C Lim, Cameron Wellard, Elizabeth Moore, Betty Gration, Bradley Augustson, Peter Mollee, Jennifer Zhang, Nicole Wong Doo, Sabine Ringkowski, Adam Bryant, Slavisa Ninkovic, Nada Hamad, Georgia McCaughan, Shaji Kumar, Andrew Spencer, Hang Quach

Blood (2024) 144 (Supplement 1): 1951.

https://doi.org/10.1182/blood-2024-207609

Published: 2024

Journal Articles

Development of a Three-Gene-Based Proliferation Score (3GPS) to Predict Proliferation Index in Newly Diagnosed Multiple Myeloma

Arwa Bohra, Surendra Dasari, Wilson I. Gonsalves, Prashant Kapoor, Saurabh Zanwar, Moritz Binder, Angela Dispenzieri, Michael M Timm, Dragan Jevremovic, S. Vincent Rajkumar, Shaji Kumar

Blood (2024) 144 (Supplement 1): 1945.

https://doi.org/10.1182/blood-2024-211902

Published: 2024

Journal Articles

Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients

Nadia Toumeh, Matthew James Rees, Morie A. Gertz, Angela Dispenzieri, Binoy Yohannan, Suheil Albert Atallah-Yunes, Prashant Kapoor, Taxiarchis Kourelis, Nelson Leung, Suzanne R Hayman, Francis Buadi, David Dingli, Joselle Cook, Rahma M Warsame, Moritz Binder, Wilson I. Gonsalves, S. Vincent Rajkumar, Shaji Kumar, Eli Muchtar

Blood (2024) 144 (Supplement 1): 3308.

https://doi.org/10.1182/blood-2024-202059

Published: 2024

NARROW

Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Bringing Hematological Malignancy Clinical Trials to Patients: Mayo Clinic LLS Impact Experience

Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy

Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma

The Mutational Landscape of Extramedullary Multiple Myeloma Reveals Novel Biologic Insights and Potential Therapeutic Targets for Exploration

Single-Cell Spatial Proteomic Characterization of Clonal Plasma Cell and Immune Cell Metabolism within the Bone Marrow Microenvironment in High-Risk Smoldering Multiple Myeloma and Its Association with Progression to Multiple Myeloma

Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis

Feasibility and Implementation of the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax

Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma

Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma

Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma

Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma

Radiomics-Based Biomarkers for Risk Stratification in Newly Diagnosed Multiple Myeloma

Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy

Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry

Development of a Three-Gene-Based Proliferation Score (3GPS) to Predict Proliferation Index in Newly Diagnosed Multiple Myeloma

Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only